Is PBYI a good stock to buy?
The financial health and growth prospects of PBYI, demonstrate its potential to outperform the market. It currently has a Growth Score of C. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.
Is Puma Biotechnology a buy?
Puma Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 1 hold rating, and 1 sell rating.
Why is Puma Biotechnology down?
After a year of declining revenue in 2020, drug manufacturer Puma Biotechnology (NASDAQ:PBYI) finds its share price struggling to hold the $10 level. With their lone approved drug showing diminishing returns, a tenuous cash position, and muted trial results, Puma is a stock to avoid.
What does Puma Biotechnology do?
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition and development of novel therapeutics for the treatment of cancer.
Why did Puma stock drop in 2019?
Here's Why. Shares in Puma fell on Tuesday after the French luxury group Kering sold part of its stake in the German sportswear company for €656 million ($773 million).
Who owns Puma Biotechnology?
Top 10 Owners of Puma Biotechnology IncStockholderStakeTotal value ($)The Vanguard Group, Inc.7.56%9,693,107BlackRock Fund Advisors5.90%7,559,565Millennium Management LLC4.25%5,448,274Athyrium Capital Management LP3.99%5,107,5256 more rows
What is PUMA drug?
The paediatric-use marketing authorisation (PUMA) is a dedicated marketing authorisation covering the indication(s) and appropriate formulation(s) for medicines developed exclusively for use in the paediatric population.
Should I buy or sell Puma Biotechnology stock right now?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Puma Biotechnology in the last year. There are currently 1 sell rating, 1...
What is Puma Biotechnology's stock price forecast for 2022?
3 brokerages have issued twelve-month price targets for Puma Biotechnology's shares. Their forecasts range from $6.00 to $12.00. On average, they p...
How has Puma Biotechnology's stock performed in 2022?
Puma Biotechnology's stock was trading at $3.04 on January 1st, 2022. Since then, PBYI stock has decreased by 14.8% and is now trading at $2.59. V...
When is Puma Biotechnology's next earnings date?
Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for P...
How were Puma Biotechnology's earnings last quarter?
Puma Biotechnology, Inc. (NASDAQ:PBYI) issued its earnings results on Thursday, May, 5th. The biopharmaceutical company reported ($0.08) earnings p...
Who are Puma Biotechnology's key executives?
Puma Biotechnology's management team includes the following people: Mr. Alan H. Auerbach , Founder, Chairman, Pres, CEO & Sec. (Age 52, Pay $5.6...
Who are some of Puma Biotechnology's key competitors?
Some companies that are related to Puma Biotechnology include Tango Therapeutics (TNGX) , Rani Therapeutics (RANI) , RAPT Therapeutics (RAPT) ,...
What other stocks do shareholders of Puma Biotechnology own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Puma Biotechnology investors own include (MDVN) (MDVN) ,...
What is Puma Biotechnology's stock symbol?
Puma Biotechnology trades on the NASDAQ under the ticker symbol "PBYI."
When will Puma Biotechnology release its earnings?
How much does Puma make?
Puma Biotechnology is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021. View our earnings forecast for Puma Biotechnology.
How much did Puma stock fall in 2021?
How much money does Puma Biotechnology make? Puma Biotechnology has a market capitalization of $311.59 million and generates $225.10 million in revenue each year . The biopharmaceutical company earns $-59,990,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.
When is the buy signal for 2021?
The Puma Biotechnology Inc stock price fell by -2.18% on the last day (Thursday, 8th Jul 2021) from $8.26 to $8.08. and has now fallen 5 days in a row. During the day the stock fluctuated 2.73% from a day low at $8.06 to a day high of $8.28. The price has fallen in 7 of the last 10 days and is down by -16.87% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -93 thousand shares and in total, 273 thousand shares were bought and sold for approximately $2.20 million.
